Phase II/Pharmacodynamic Study of the gamma-secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-line Chemotherapy for Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2015
At a glance
- Drugs RG 4733 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 17 Nov 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 21 Dec 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.